Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings
Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…Quantitative Keyboard Tapping Measurement Correlates with Electrophysiological Changes in STN LFPs of PD Patients Treated with L-dopa Better Than UPDRS Subscores
Objective: Reliable and objective assessment of the symptoms of patients with Parkinson’s disease (PD) and the correlation of the measures with neural patterns is important…Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies
Objective: (1) To investigate the natural history of Parkinson’s disease (PD) in a cohort of newly diagnosed patients and (2) the response to acute levodopa…ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
Objective: To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Quantitative Assessment of Appendicular Bradykinesia in Parkinson’s Disease using Wearable Sensors
Objective: To quantify appendicular bradykinesia during a repetitive motor task in patients with Parkinson’s disease. Background: Bradykinesia is a cardinal motor symptom of Parkinson’s Disease…Depression (BDI-II) in Parkinson’s disease: Prevalence, types, and variables associated to major, minor and subclinical depression in COPPADIS cohort
Objective: To know the prevalence and characteristics of depression in PD patients of the COPPADIS-2015 cohort and its relationship with the other clinical aspects of…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?
Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 57
- Next Page »